Online Program Home
My Program

Abstract Details

Activity Number: 263
Type: Contributed
Date/Time: Monday, August 1, 2016 : 2:00 PM to 3:50 PM
Sponsor: Biopharmaceutical Section
Abstract #321198
Title: The Three-at-Risk Design: Reducing the Duration of Phase I Trials with a Queue-Based Method
Author(s): Paul Frankel* and Jeffrey Longmate and Richard Sposto and Edward Newman and Susan Groshen
Companies: City of Hope and City of Hope and University of Southern California and City of Hope and University of Southern California
Keywords: Phase I ; queuing theory ; oncology
Abstract:

Purpose: The 3-at-risk method is a modification of the 3+3 design that seeks to reduce the duration of Phase I studies subject to the traditional risk constraints. Methods: We designed the 3-at-risk method to adapt to asynchronous patient arrival and evaluation, screen failures and patient inevaluabilty, constrained by the maximum level of individual patient risk permitted during a traditional 3+3 design. Simulations explore the impact of inevaluability, screen failure, patient arrival patterns and the underlying dose-toxicity relationship. Results: With clinically relevant parameters, simulations comparing the 3-at-risk method to the 3+3 method demonstrate approximately a 1-month reduction in the average duration of a Phase I clinical trial for every year the study is accruing. Simulations suggested a small (0-2 patient) increase in the median total number of patients required to complete a trial with the 3-at-risk design, representing the trade-off required to obtain the reduction in study duration. Conclusion: The 3-at-risk design reduces the expected Phase I study duration when compared to the traditional 3+3 design while limited to traditional risk.


Authors who are presenting talks have a * after their name.

Back to the full JSM 2016 program

 
 
Copyright © American Statistical Association